MedCap AB (OSTO:MCAP) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
81 GF Score
Price kr560.00
GF Value kr566.23
Valuation Fairly Valued
View Full Analysis

What is MedCap AB 5-Year Yield-on-Cost %?

MedCap AB OSTO:MCAP +12.31% 81 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 81/100 and a GF Value™ of kr566.23 (Fairly Valued). Among 323 Medical Devices & Instruments companies, MedCap AB ranks worse than 309597.21% on this metric.

MedCap AB's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for MedCap AB's 5-Year Yield-on-Cost % or its related term are showing as below:



OSTO:MCAP's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.42
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

MedCap AB  (OSTO:MCAP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


MedCap AB 5-Year Yield-on-Cost % Related Terms


OSTO:MCAP vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, MedCap AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where MedCap AB's 5-Year Yield-on-Cost % falls into.


OSTO:MCAP
81GF Score
MedCap AB OSTO:MCAP
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of MedCap AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
MedCap AB (OSTO:MCAP) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #999999 out of 323 companies in the Medical Devices & Instruments industry.
Is MedCap AB's 5-Year Yield-on-Cost % too high?
MedCap AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, MedCap AB ranks #999999 out of 323 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MedCap AB has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #999999 out of 323 companies for 5-Year Yield-on-Cost %. This places MedCap AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.42, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr566.23, compared to a current price of kr560.00 — trading 1.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. MedCap AB's overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr560.00 is trading 1.1% below its estimated GF Value™ of kr566.23. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: kr566.23 vs. price of kr560.00 (1.1% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
81GF Score

Get the complete analysis for OSTO:MCAP

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr560.00
Price
kr566.23
GF Value